Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00015938 · ClinicalTrials.gov registry record · Phase 2
S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer
A Phase 2 study of Breast Cancer, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
- 20
- Study locations
NCT00015938 is a Phase 2 study of Breast Cancer that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 95 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT00015938, a Phase 2 study of Breast Cancer, has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combining docetaxel, vinorelbine, and filgrastim in treating women who have stage IV breast cancer.
Conditions Studied
Interventions
- DRUG docetaxel
- DRUG vinorelbine
- BIOLOGICAL filgrastim
Study Locations (20)
California
- City of Hope Comprehensive Cancer Center - Duarte
- USC/Norris Comprehensive Cancer Center and Hospital - Los Angeles
- Veterans Affairs Medical Center - West Los Angeles - Los Angeles
- Jonsson Comprehensive Cancer Center, UCLA - Los Angeles
- Veterans Affairs Outpatient Clinic - Martinez - Martinez
- CCOP - Bay Area Tumor Institute - Oakland
- Chao Family Comprehensive Cancer Center at University of California Irvine Cancer Center - Orange
- University of California Davis Cancer Center - Sacramento
- CCOP - Santa Rosa Memorial Hospital - Santa Rosa
- David Grant Medical Center - Travis Air Force Base
Arizona
- CCOP - Western Regional, Arizona - Phoenix
- Veterans Affairs Medical Center - Phoenix (Carl T. Hayden) - Phoenix
- Veterans Affairs Medical Center - Tucson - Tucson
- Arizona Cancer Center at University of Arizona Health Sciences Center - Tucson
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
- Veterans Affairs Medical Center - Little Rock (McClellan) - Little Rock
Colorado
- University of Colorado Cancer Center at University of Colorado Health Sciences Center - Denver
- Veterans Affairs Medical Center - Denver - Denver
Alabama
- MBCCOP - Gulf Coast - Mobile
Alaska
- Providence Alaska Medical Center - Anchorage
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2001-05 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00015938
The ClinicalTrials.gov registry entry for NCT00015938 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (97% lower). The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which docetaxel is the first listed.
NCT00015938 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00015938 about?
NCT00015938 is a clinical study titled "S0102: Docetaxel, Vinorelbine, and Filgrastim in Treating Women With Stage IV Breast Cancer". RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from th...
What is the current status of trial NCT00015938?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2001-05. Estimated completion is 2012-11.
What conditions does trial NCT00015938 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00015938?
The interventions under investigation include: docetaxel (DRUG), vinorelbine (DRUG), filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00015938?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00015938 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RECRUITING · Phase 2
-
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
RECRUITING · Phase 2
-
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
RECRUITING · Phase 2
-
Precision Medicine in Action: Phase II Trial of Response Adaptive Ablative Pre-operative SPBI (RAPS) and Non-operative Sentinel Lymph Node Biopsy in Patients With Early-stage ER+ Breast Cancer: RAPS Trial
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.